Old Web
English
Sign In
Acemap
>
authorDetail
>
Itzel A Harriott
Itzel A Harriott
Clinical endpoint
Medicine
Adverse effect
Internal medicine
Vulvovaginal Candidiasis
3
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: a phase 3, randomized, controlled superiority trial (VANISH 303)
2021
Clinical Infectious Diseases
Jane R. Schwebke
Ryan Sobel
Janet K Gersten
Steven A. Sussman
Samuel N. Lederman
Mark Jacobs
B. Todd Chappell
David L. Weinstein
Alfred H. Moffett
Nkechi Azie
David Angulo
Itzel A Harriott
Katyna Borroto–Esoda
Mahmoud A. Ghannoum
Paul Nyirjesy
Jack D. Sobel
Show All
Source
Cite
Save
Citations (1)
Phase 2 randomized study of oral ibrexafungerp vs fluconazole in vulvovaginal candidiasis.
2021
Clinical Infectious Diseases
Paul Nyirjesy
Jane R. Schwebke
David Angulo
Itzel A Harriott
Nkechi Azie
Jack D. Sobel
Show All
Source
Cite
Save
Citations (1)
Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306).
2021
British Journal of Obstetrics and Gynaecology
Ryan Sobel
Paul Nyirjesy
Mahmoud A. Ghannoum
Dimitar A Delchev
Nkechi Azie
David Angulo
Itzel A Harriott
Katyna Borroto–Esoda
Jack D. Sobel
Show All
Source
Cite
Save
Citations (0)
1
map